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Abstract
Cardiac magnetic resonance imaging (CMR) has become an indispensible imaging technique
for the diagnosis and treatment of patients with cardiovascular diseases. Technical advances
in the past have rendered CMR unique in the evaluation of cardiovascular anatomy, physio-
logy, and pathophysiology due to its unique ability to produce high resolution tomographic
images of the human heart and vessels in any arbitrary orientation, with soft tissue contrast
that is superior to competing imaging modalities without the use of ionizing radiation. CMR
imaging is the gold standard for assessing left and right ventricular function and for detecting
myocardial tissue abnormalities like edema, infarction, or scars. For prognostic reasons ab-
normal structure and dysfunction of the heart, and the detection of myocardial ischemia and/
/or myocardial scars are the main targets for CMR imaging. In this review we briefly describe
the prognostic significance of several CMR imaging techniques and special CMR parameters
in patients with coronary artery disease (CAD), with cardiomyopathies, and with chronic
heart failure. Myocardial ischemia proved to be a strong predictor of an adverse outcome in
patients with CAD. Microvascular obstruction in acute myocardial infarction is a new and
independent parameter of negative left ventricular remodeling and a worse prognosis. Myocar-
dial scars in patients with CAD and unrecognized myocardial infarction heralds a negative
outcome. Scar in patients with dilated or hypertrophic cardiomyopathy are a strong predictor of
both life-threatening ventricular tachyarrhythmias and prognosis. CMR imaging may improve
the assessment of inter- and intraventricular dyssynchrony and provide prognostic informa-
tion by detecting myocardial scars. (Cardiol J 2010; 17, 6: 549557)
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Clinical significance of cardiac
magnetic resonance imaging
Magnetic resonance imaging (MRI) has be-
come a unique tool for investigating the morpholo-
gy and function of the cardiovascular system. The
strength of cardiac magnetic resonance (CMR) is
based on its high spatial and temporal resolution,
the high blood-tissue contrast particularly when
using the steady-state free precession (SSFP) tech-
niques, and the capability of three-dimensional (3D)
reconstruction of cardiac and vascular structures.
In contrast to echocardiography, MRI is largely user
independent and does not substantially suffer from
variations in image quality and poor patient-relat-
ed echogenicity. It is independent of slice-orienta-
550
Cardiology Journal 2010, Vol. 17, No. 6
www.cardiologyjournal.org
tion or acoustic window, and its 3D nature enables
direct calculation of ventricular dimensions without
any need of geometrical models. Most importantly,
MRI enables direct visualization of myocardial per-
fusion (T1 weighting imaging after gadolinium con-
trast injection), and the identification of myocardial
edema (by native T2 weighted imaging). Equally
important appears the capability to detect myocar-
dial tissue abnormalities such as necrosis or scar
using the late gadolinium enhancement (LGE) tech-
nique. Lastly, this imaging technique completely
avoids biological damage to the patient in contrast
to radiation exposure from nuclear or x-ray tech-
niques (e.g. computed tomography etc).
For prognosis abnormal structure and dysfunc-
tion of the heart are the main targets for CMR im-
aging. The main parameters identifying ventricu-
lar dysfunction are accurate and reproducible mea-
surements of ventricular dimensions, mass and
function, as well as the detection and quantitation
of areas of LGE.
In the following we will comprehensively re-
view published data on the prognostic significance
of several CMR imaging techniques in patients with
coronary artery disease (CAD), with cardiomyopa-
thies, and with chronic heart failure (HF).
Chronic stable coronary artery disease
Inducible myocardial ischemia
Dobutamine stress CMR and myocardial first
pass perfusion during adenosine stress are the two
main CMR techniques widely used to detect myo-
cardial ischemia [13]. Imaging of stress-induced
myocardial ischemia cannot only be used for detect-
ing or excluding flow limiting coronary artery
stenoses, but also for evaluating prognosis.
For instance dobutamine stress CMR (DSMR)
has been used [4] for preoperative risk stratifica-
tion, in a subgroup of patients with intermediate risk
prior to a non-cardiac surgical procedure, positive
DSMR test was an independent predictor of myo-
cardial infarction, cardiac death, or HF during or af-
ter surgery. Jahnke et al. [5] evaluated the prognos-
tic value of DSMR and CMR-first pass perfusion
(FPP) in 533 patients with chest pain or dyspnea
and suspected CAD. The 3-year event-free survi-
val was 99.2% for patients with normal DSMR and
FPP and 83.5% for those with abnormal DSMR and
FPP. By multivariate analysis, ischemia on magnet-
ic resonance testing (either DSMR or FPP) was an
independent predictor of cardiac events. The cumu-
lative event rate for an abnormal DSMR at 1-, 2-,
and 3-year was 7.3, 10.3, and 18.8,, and for an ab-
normal FPP 6.2, 12.2, and 16.3, respectively. More-
over, an abnormal CMR stress test result had sig-
nificant incremental value over clinical risk factors
and resting wall motion abnormality (p < 0.001). In
another study by Hundley et al. [6] DSMR has also
been used for determining the prognosis of 279 pa-
tients with suspected CAD, who could not be stud-
ied adequately using transthoracic stress echocar-
diography. In a multivariate analysis, the presence
of inducible myocardial ischemia by DSMR (hazard
ratio [HR] 3.3) or an left ventricular ejection frac-
tion (LVEF) < 40% (HR 4.2) was associated with
future myocardial infarction (MI) or cardiac death
independent of the presence of risk factors for cor-
onary arteriosclerosis.
Several studies have also reported on the prog-
nostic significance of CMR-FPP. Pilz et al. [7] fol-
lowed 218 patients with suspected CAD and a neg-
ative MR perfusion test. The 12-month rate of ma-
jor adverse cardiovascular events (MACE) was 2 of
218 patients with no cardiac death or MI, and the
negative predictive value of a negative MR first pass
perfusion was 99.1%. The authors concluded that
a negative first pass perfusion result may reduce
the number of redundant coronary angiographies.
Jahnke et al. [5] showed that a myocardial perfu-
sion defect on FPP is associated with a HR of
10.6 for the endpoints cardiac death or MI over
a follow-up period of 2.3 years. Bodi et al. [8] per-
formed dipyridamole stress CMR and FPP in a se-
ries of 420 patients with chest pain and known or
suspected CAD. MACE rate after a median follow-
up period of 420 days was significantly higher in
patients with inducible perfusion defects compared
to patients without a perfusion defect (17% vs 5%).
This was also the case for presence vs absence of
LGE (20% vs 6%). However, in a multivariate ana-
lysis adjusted for baseline characteristics, the extent
of wall motion abnormalities on dipyridamole stress
was independently related to the MACE rate. FPP
studies may also be useful in patients with acute
chest pain, as demonstrated by Ingkanisorn et al.
[9] in 135 troponin-negative patients admitted to the
emergency department. Patients with a negative
stress test had a 100% event-free survival after
1 year follow-up (no subsequent diagnosis of CAD
or an adverse outcome), compared with only 20%
with a perfusion defect in FPP. Thus, it may be con-
cluded that whenever myocardial ischemia can be
excluded in patients with suspected or known CAD
by either DSMR or FPP, these patients will have
a favourable outcome prospectively.
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Unrecognized myocardial scar
Late gadolinium enhancement CMR (LGE-
-CMR) has shown excellent sensitivity and specific-
ity for detection of even small myocardial scar. Fur-
thermore, there is some data indicating that LGE
imaging can reveal previously unknown MI, and that
the presence of LGE has a strong prognostic im-
pact. Unrecognized myocardial scar is more fre-
quent than expected. In a population-based study
in Sweden by Barbier et al. [10] including 259 ran-
domly selected individuals aged 70-years, LGE in-
dicating scar was detected in 19.8% of the sub-
jects without a history of MI. The prevalence of un-
recognized myocardial scar seems to be increased
in patients with higher cardiovascular risk. In
a study by Kwong et al. [11] LGE was present in
44 of 195 patients with suspected CAD but without
known prior MI. The authors were able to show that
the presence of even small amounts of LGE indi-
cates a high risk and provides incremental prognos-
tic value for MACE and cardiac mortality beyond
common clinical, angiographic, and functional pre-
dictors. In another study the same group found sim-
ilar results in diabetic patients without known pri-
or infarction [12]. The presence of LGE as a sign of
previous coronary events was the strongest predic-
tor for an adverse cardiac outcome. These findings
strongly support the general use of LGE imaging
in patients with suspected CAD for improving risk
assessment.
Acute myocardial infarction
Peri-infarct zone and
ventricular arrhythmias
Ventricular arrhythmias and sudden cardiac
death (SCD) are a major cause of morbidity and mor-
tality in the post-MI period. The border zone of an
infarct is often composed of areas of viable myocar-
dium interspersed with infarcted tissue or scar,
which can become a substrate for impaired conduc-
tion and re-entrant circuits as a prerequisite of
malignant ventricular tachyarrhythmias. It has been
postulated that this peri-infarct zone can be visua-
lized by CMR on LGE images as areas along the
infarct border of intermediate signal intensity.
Schmidt et al. [13] studied 40 patients undergoing
an electrophysiology study (EPS) prior to implant-
able cardioverter-defibrillator (ICD) implantation
for primary prevention of SCD and found that the
size of the infarct border zone measured by CMR
predicted inducibility of monomorphic ventricular
tachycardia (VT) on EPS. Yan et al. [14] reported
that the size of the peri-infarct zone measured by
CMR was predictive for all cause and cardiac mor-
tality over 2.4 years of follow up. Roes et al. [15]
found in a CMR study of 91 post-MI patients sche-
duled for ICD implantation for either primary or se-
condary prevention of SCD that the size of the peri-
infarct zone was a stronger predictor of appropri-
ate ICD therapy, as a surrogate for SCD as
compared to LVEF or total infarct size. Heidary et
al. [16] could confirm these results in a study of
70 patients with a history of MI and ischemic cardio-
myopathy, who were evaluated for ICD implanta-
tion and followed for 18 months. They could show
that the size of the peri-infarct zone as well as total
infarct size were predictive of cardiac events. Thus,
it seems that LGE-based assessment of the struc-
ture and extent of the peri-infarct zone may provide
a non-invasive parameter of an increased risk of
post-MI patients of malignant ventricular arrhyth-
mias and adverse outcome.
Myocardial infarct size
CMR-based assessment of infarct size using
LGE is well validated (Fig. 1). Infarct size has been
reported to be highly predictive for cardiac events
at follow up. Yokota et al. [17] were able to show in
86 patients with prior MI followed for an average
of 20 months that infarct size by LGE was a better
predictor of cardiac events than LVEF, LV end-systo-
lic volume (LVESV) or LV end-diastolic volume
(LVEDV). Similar results were obtained by Cheong
Figure 1. Late gadolinium enhancement image of a pa-
tient with acute anteroseptal myocardial infarction in
a 2-chamber view. Note the bright areas of contrast
accumulation (= infarcted myocardium), and some in-
tramural (intra-infarct) dark areas indicating microva-
scular obstruction.
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et al. [18] in a cohort of 857 patients with and with-
out CAD followed for a median of 4.4 years. They
demonstrated that presence of LGE, reduced LVEF
and HF symptoms were independent predictors of
mortality. It was also shown that patients with LGE
and an ejection fraction more than 50% had the
MACE rates as those with an LVEF less than 50%
without presence of LGE. These results were again
corroborated by Larose et al. [19] in 103 acute ST
elevation MI (STEMI) patients undergoing CMR
within 12 hours and 6 month after percutaneous
coronary intervention (PCI) and follow-up of an
average of 2.4 years. They demonstrated that LGE
size measured immediately after revascularization
strongly and independently predicted recovery of
LVEF after 6 months and long-term major cardiac
events better than initial LVEF or clinical parame-
ters. Wu et al. [20] found similar results in 122
STEMI patients who received CMR after revascu-
larization and were followed for 2 years; infarct size
was again a stronger indicator of worsened LV sys-
tolic function and clinical outcomes at follow up than
were baseline measurements of LV systolic func-
tion. In addition, Plein et al. [21] were able to show
that the ratio of infarct size (by LGE) to the extent
of ischemia (visualized by adenosine stress first
pass perfusion) was significantly higher in patients
with Q-wave STEMI than in those with non-Q-wave
STEMI or non-STEMI, while conversely, the
amount of ischemia present was higher in NSTEMI
patients than in STEMI patients, whereas the total
area of ischemia and infarction was not different
between the three groups.
Right ventricular infarction
Right ventricular (RV) infarction classically
occurs along with an inferior LV infarction due to
proximal occlusion of the right coronary artery. RV
infarction is usually diagnosed by physical exami-
nation, ST elevation on right-sided electrocardio-
gram leads, or by echocardiographic evidence of RV
dysfunction. However, CMR has been demonstrat-
ed to be much more sensitive for detecting small
or medium RV infarcts than physical exam, ECG or
echocardiography [22]. In a study of Jensen et al.
[22] on 50 patients LGE indicating RV involvement
was detected in 54% of patients (in 14 of 30 patients
with inferior STEMI, and in 13 of 20 patients with
anterior STEMI) with LGE-CMR. In a multivariate
logistic regression model RV involvement was
a strong independent predictor (odds ratio 15.8; car-
diac index 463%) of major cardiac adverse events
within a follow-up of 32 – 8 months, even after nor-
malization for LV infarct size and location [10, 13].
Bueno et al. [23] studied 198 elderly patients with
inferior MI, 75% of whom did not receive revascu-
larization. RV infarction in this cohort occurred in
41%, with a mortality of 47%, compared to 10%
mortality in those without RV infarction. The inci-
dence of cardiogenic shock, atrioventricular conduc-
tion block, and rupture of the interventricular sep-
tum was also markedly higher in those with RV in-
volvement. In a more recent study by Giannitsis et
al. [24] of 88 inferior MI patients, 87 of whom un-
derwent PCI, RV infarction was present in 31% but
did not show any significant short-term prognostic
implications. These results were corroborated in
a CMR study by Hombach at al. [25] of 110 MI pa-
tients followed for 7.5 months, 85% of whom were
revascularized by PCI. Late gadolinium enhance-
ment of the RV was seen in 17% of these patients,
with RV wall motion abnormalities in 43%. RV in-
farction in this study was not associated with a worse
outcome. On the other hand, RV infarction by LGE
after MI was shown to be predictive of RV dilation
at 6 month follow up [26]. In conclusion, RV involve-
ment in acute MI can be reliably detected by CMR,
but the prognostic significance of LGE of the right
ventricle remains unclear based on the present re-
sults in the literature.
Microvascular obstruction
In about 20% to 50% of patients with an acute
MI a slow-flow or no-reflow phenomenon in the
infarcted myocardium can be observed, despite
modern acute mechanical recanalization techniques
(i.e. primary PCI and concomitant medical therapy
with GP IIb/IIIa). This phenomenon is also called
microvascular obstruction (MVO) and can be as-
sessed by CMR using two separate techniques.
Early MVO is visualized early after first pass per-
fusion as hypoenhancement persisting longer than
1 to 2 min after contrast injection. The second tech-
nique uses LGE images 10 to 15 min after contrast
injection, and MVO appears as an area of hypoen-
hancement encompassed within the core of hyper-
enhanced infarcted myocardium, often extending
from the subendocardium (Fig. 2). This latter meth-
od in the literature is sometimes termed late MO
or persistent MO (PMO) [25]. There is still no de-
finite consensus on whether early or late MO should
be the preferred technique for evaluating MO. Wu
et al. [27] found that the spatial extent of early MO
correlates well with histology and myocardial con-
trast echo. Orn et al. [28] reported that early MO
was predictive of LV function and remodeling at one
year follow up, and was a better marker of 1 year
infarct size than late MO. Wu et al. [29] found that
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early MO predicts infarct transmurality, LV func-
tion and remodeling after 16 months, and is also
a powerful independent prognostic indicator of
MACE even after normalization for infarct size. In
contrast, Nijveldt et al. [30] found in a study of
60 MI patients undergoing CMR at 5 days and
4 months that both early and late MO correlated with
poor ST segment resolution. None of both methods
correlated well with angiographic parameters such
as angiographic blush grade or TIMI flow grade.
On the other hand late MO (PMO) correlates
with invasive coronary flow velocity measures of
MVO [31], and several studies have shown that
PMO better predicted follow up LV function and re-
modeling than early MO, and provides additional
prognostic information beyond that of infarct size
or transmurality. For example, Nijveldt et al. [32]
studied 63 acute MI patients who received PCI and
optimal medical management and followed them by
CMR with assessment of early, mid, and late MO
4 to 7 days after MI and follow up CMR at 4 months.
They reported that PMO was a better predictor of
follow up LVEF, LVEDV and LVESV than early
MO. In a study of 110 MI patients, Hombach et al.
[25] found that PMO was an independent predictor
of LV remodeling, and independently indicated an
increase in cardiac events at 8 month follow up and
gave additional prognostic information than infarct
size alone. This was corroborated in a CMR study
of Bruder at al. [33] on 67 STEMI patients followed
for 14 months, showing that late MO was a better
predictor of adverse cardiac events than infarct size
or baseline ejection fraction. The timing of the CMR
examination after MI is also important when assess-
ing MO using first pass perfusion. Studies demon-
strate that early MO is more often seen when CMR
is performed 2 days after MI than on days 7 or 9,
but is not predictive of long term functional or clin-
ical outcomes until the later time points [28, 29]. It
can be concluded that if MO either early or late is
present in a patient in the acute phase of MI this
patient has a worse prognosis compared with a pa-
tient without MO. Thus, the detection of MO after
MI may force to adhere strictly to modern standard
medical therapy, and to monitor patients with pres-
ence of MO post-MI closer and more strictly than
those without MO.
Ischemic cardiomyopathy
Patients with ischemic cardiomyopathy (ICM)
have a limited prognosis, and in addition to de-
pressed LV function and electrocardiographic pre-
dictors of potentially life-threatening ventricular ta-
chyarrhythmias or SCD CMR may provide indepen-
dent prognostic information in this patient group.
Yokota et al. [17] studied 86 patients with ICM with
a mean LVEF of 26 – 12% using delayed-enhance-
ment CMR with a follow-up of 20 – 16 months.
Patients with cardiovascular events had significant-
ly larger scar volume and scar percentage of the
myocardium than patients without events. Quanti-
fication of scar volume was superior to LVEDV,
LVESV, and LVEF in predicting future cardiovas-
cular events in ICM patients. Similar results were
reported by Kwon et al. [34] in 349 patients with
ICM and severely reduced LVEF. Mean scar per-
Figure 2. Microvascular obstruction in a patient with posterolateral myocardial infarction from occlusion of the left
circumflex artery (A), and in a patient with anteroseptal infarction (B) in the short axis view. Note the area of
hypoenhancement encompassed within the core of hyperenhanced infarcted myocardium (A), and the hypoenhan-
ced area of microvascular obstruction extending from the subendocardium (B).
A B
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centage and transmurality score were significantly
higher in patients with events vs those without
events. Kim et al. [35] using CMR imaging with
delayed enhancement (LGE) were able to show in
a systematic study in 185 patients with suspected
CAD without clinical or electrocardiography (ECG)
evidence of prior infarction that unrecognized non-
-Q-wave MI by LGE was associated with an 11-fold
higher mortality risk independent of LVEF.
Non-ischemic cardiomyopathies
Idiopathic dilated cardiomyopathy (IDC)
CMR may also provide additional prognostic
information in patients with dilated cardiomyopa-
thy and/or HF by both left and right ventricular func-
tion and LGE. Nazarian et al. [36] reported in 26 pa-
tients with non-ICM predominance of scar locali-
zation and distribution, that a transmural extent of
LGE of 26% to 75% of wall thickness was signifi-
cantly predictive of inducible VT on EPS and re-
mained predictive after adjustment for LVEF (odds
ratio 9.125, p = 0.020). Thus, scar distribution may
identify the substrate for inducible VT and may
identify high-risk patients with non-ICM. Similar
results were reported by Yokokawa et al. [37] in
47 patients with IDC and advanced HF.
In a total of 101 consecutive patients with non-
ICM and HF Asomull et al. [38] found midwall fi-
brosis by LGE-CMR in 35%, which was associated
with a higher rate of the predefined combined end-
point (all-cause death and hospitalization for a car-
diovascular event, HR 3.4, p = 0.01) and for pre-
diction of secondary endpoint (SCD and/or sus-
tained VT, HR 5.2, p = 0.03). Wu et al. [39] found
LGE in 27 (42%) patients in a series of 65 patients
with non-ICM and ejection fraction £ 35% planned
for an ICD implantation, and 12 of LGE positive pa-
tients (44%) had an index composite outcome event
(cardiac death, appropriate ICD shock, and hospital-
ization for decompensated HF) compared with only
8% of LGE negative patients (p < 0.001). After ad-
justment for LV volume index and functional class,
patients with LGE had an 8-fold higher risk of expe-
riencing the primary endpoint (HR 8.2, p = 0.002).
Hombach et al. [40] studied 141 consecutive
IDC patients by clinical, conventional ECG, CMR
functional parameters, and LGE-CMR. In 63 pa-
tients myocardial biopsy was performed, and chron-
ic inflammation was excluded by molecular analy-
sis. Non-CAD type mid-wall or subepicardial LGE
was present in 36 (26%) patients. After median fol-
low-up of 1339 days including 483 patient years
25 (18%) patients experienced the primary endpoint
(cardiac death 16, sudden death 3 plus 6 with an ICD
shock). Kaplan-Meier analysis showed QRS duration
> 110 ms (p = 0.010), presence of LGE (p = 0.037),
and diabetes mellitus (p < 0.001) as significant pre-
dictors of a worse outcome. Multivariable analysis
revealed cardiac index (p < 0.001) and increased
RVEDVI (p = 0.006) derived from CMR, the pre-
sence of diabetes mellitus (p = 0.006), and QRS
> 110 ms (p = 0.0045) as significant predictors of
the primary endpoint. In conclusion, it was stressed
that prognostically relevant hemodynamic (cardiac
index, RVEDVI) and ECG parameters (QRS dura-
tion) can be derived from two non-invasive tech-
niques with highest precision and without compli-
cated analysis techniques.
Hypertrophic cardiomyopathy
Recent publications have shown that in patients
with hypertrophic cardiomyopathy (HCM) the extent
of fibrosis or scar as documented by LGE (Fig. 3) is
associated with the prevalence of ventricular (ta-
chy-) arrhythmias and with a worse prognosis. Ad-
abag et al. [41] reported in a cohort of 177 HCM
patients that patients with LGE had a greater num-
ber of PVCs, couplets, and non-sustained VT (nsTV)
episodes than those without LGE; LGE was an in-
dependent predictor of nsVT. Suk et al. [42] report-
ed in 25 HCM patients that VT occurred in 32% of
patients and this was associated with both increased
scar mass (by LGE) and wall thickness, compared
with non-VT patients. Fluechter et al. [43] found in
a retrospective study on 76 consecutive HCM pa-
tients that 12 of 38 high-risk patients (defined by
1 or more of the conventional risk factors) had in-
ducible VT on EPS, and the relative LV mass with
LGE was significantly higher in patients with induc-
ible VT compared with those without (22% vs 10%,
p = 0.03). Leonardi et al. [44] reported similar re-
sults. In a cohort of 108 consecutive HCM patients
they found that compared to patients without arrhyth-
mias patients with VT/VF (n = 33) had a higher LGE
score, and the LGE score was the only independent
predictor of VT/VF in multivariable analysis; LGE
score, maximal LV wall thickness, and LV mass in-
dex were significantly greater among patients at risk
for SCD (n = 51) compared with the remaining
57 patients at low risk. The authors concluded that in
HCM patients several CMR parameters are associa-
ted with risk for SCD, and a semi-quantitative LGE
score is a significant predictor of both clinical VT/VF
and of risk for SCD, and may contribute to risk as-
sessment in borderline or controversial cases.
OHanlon et al. [45] assessed the presence and
amount of myocardial fibrosis by LGE in 217 con-
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secutive HCM patients and prospectively followed
them over 3.1 – 1.7 years. Thirty-four of the 136 pa-
tients (25%) in the fibrosis group but only 6 of
81 without fibrosis reached the combined primary end-
point of cardiovascular death, unexplained cardio-
vascular admission, sustained VT or VF, or appro-
priate ICD shock (HR 3.4, p = 0.006). The extent
of fibrosis and nonsustained VT were univariable
predictors of arrhythmic endpoints (sustained VT
or VF), appropriate ICD discharge, or SCD (HR 1.3,
p = 0.04). In multivariable analysis only nonsus-
tained VT remained an independent predictor of ar-
rhythmic endpoints, whereas the extent of fibrosis
did not. Bruder et al. [46] enrolled 243 HCM pa-
tients, who were investigated by a comprehensive
CMR protocol including LGE-CMR, and follow-up
was completed in 220 patients after mean 1,090 days
for all-cause and cardiac mortality. The presence of
scar visualized by CMR yielded an odds ratio of 5.47
for all-cause mortality and 8.01 for cardiac mortali-
ty. This seemed to be superior to classical clinical
risk factors, because in their dataset the presence
of 2 risk factors yielded an odds ratio of 3.86 for all-
cause mortality and of 2.20 for cardiac mortality.
Multivariable analysis also revealed the presence
of LGE as a good independent predictor of death in
HCM patients. Thus, it may be concluded that the
presence and extent of myocardial fibrosis as detect-
ed by LGE on CMR imaging heralds an adverse out-
come in HCM patients and may be superior to the
known classical clinical risk factors. CMR imaging
may offer new access to a better risk stratification
not only in patients with advanced, but also with
borderline disease states of HCM.
Patients with chronic heart failure
Cardiac magnetic resonance derived
dyssynchrony in heart failure
CMR imaging is useful in patients with chronic
HF not only for assessing ventricular dysfunction,
myocardial scar, and prognosis, but also for detect-
ing and quantifying the amount of inter- and parti-
cularly intraventricular dyssynchrony and its prog-
nostic impact. Chalil et al. [47] were able to show
that the CMR derived tissue synchronization index
(TSI) as a parameter of LV dyssynchrony had prog-
nostic impact in 77 patients with HF undergoing
cardiac resynchronization therapy (CRT). Kaplan-
-Meier curves showed that patients with a TSI
‡ 110 ms had a worse outcome regarding survival
from hospitalization for MACE, hospitalization for
HF, survival from death from any cause, and sur-
vival from cardiovascular death. These results are
puzzling as on one hand LV dyssynchrony is a pre-
dictor of increased mortality in patients with HF,
on the other hand CRT should improve outcome and
clinical symptoms in patients with HF. This discre-
pancy may be explained by the study of Leyva et al.
[48], who developed a triple index to predict sur-
vival after CRT. Out of 16 prognostic risk factors
of HF patients, Cox proportional hazards analyses
revealed dyssynchrony, postero-lateral scar and
elevated creatinine as independent predictors of
cardiovascular mortality (DSC index). Compared to
patients with a DSC < 3, cardiovascular mortality
in patients in the intermediate DSC index (35; HR
11.1, p = 0.0003) and high DSC index group (‡ 5;
HR 30.5, p < 0.0001) was significantly higher. In
Figure 3. Myocardial fibrosis (scar) in a patient with hypertrophic cardiomyopathy in a short axis (A) and four-
-chamber view (B). Note the hyperenhanced area within the interventricular septum in the region of greatest
thickness of the septal wall.
A B
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this study hazard ratio of postero-lateral scar loca-
tion was 12.2 compared to CMR-TSI with a hazard
ratio of 1.01 and creatinine with a hazard ratio of
1.01, and thus, postero-lateral scar was the most
powerful prognostic parameter within this triple
DSC index. In conclusion, CMR assessment of in-
traventriular dyssynchrony and detection of myo-
cardial scar by CMR imaging appear to be promis-
ing new parameters of risk stratification in patients
with chronic HF and significant dyssynchrony.
However, further prognostic studies have to be per-
formed to validate these preliminary results.
Conclusions
CMR is an essential technique for characteri-
zation of patients with cardiovascular disease. It
allows accurate assessment and quantification of
many parameters such as ventricular function/dys-
function, myocardial ischemia, and myocardial dam-
age/scar with highest precision and without radia-
tion exposure. Several CMR-derived parameters
provide significant prognostic information in pa-
tients with CAD, with cardiomyopathies, and with
chronic HF. Myocardial ischemia, either detected
by dobutamine stress CMR or by CMR first pass
perfusion, is a strong predictor of an adverse out-
come in patients with suspected or known CAD.
Microvascular obstruction in patients with acute MI
is a new and independent parameter of negative LV
remodeling and a worse prognosis. Moreover, de-
monstration of myocardial scar in patients with known
or suspected CAD and unrecognized MI by delayed
enhancement-CMR (LGE) heralds a negative out-
come. Fibrosis or scar in patients with dilated
as well as with hypertrophic cardiomyopathy is
a strong predictor of both life-threatening ventric-
ular tachyarrhythmias and prognosis. Preliminary
data indicate that CMR imaging may not only im-
prove the assessment of inter- and particularly in-
traventricular dyssynchrony in patients with severe
LV dysfunction to be selected for CRT, but also may
aid in selecting CRT responders and provide prog-
nostic information by detecting myocardial scars
using the LGE technique.
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